pulmonary arterial hypertension

Merck & Co., Acceleron, pulmonary arterial hypertension, clinical trial data, sotatercept, STELLAR, SOTERIA, ERS 2023, FDA

Merck showcases new data on sotatercept for PAH, awaits FDA decision

Anika Sharma

Merck & Co. has unveiled new clinical data on sotatercept, reinforcing the drug candidate’s safety and efficacy in the treatment ...